[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,195,365
  • Shares Outstanding, K 195,806
  • Annual Sales, $ 502,080 K
  • Annual Income, $ -724,930 K
  • EBIT $ -523 M
  • EBITDA $ -512 M
  • 60-Month Beta 1.02
  • Price/Sales 26.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 47.00% (-7.14%)
  • Historical Volatility 40.07%
  • IV Percentile 15%
  • IV Rank 20.84%
  • IV High 80.30% on 02/05/26
  • IV Low 38.24% on 06/12/25
  • Expected Move (DTE 5) 3.41 (5.06%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 1,209
  • Volume Avg (30-Day) 2,219
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 63,023
  • Open Int (30-Day) 50,004
  • Expected Range 63.98 to 70.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.61
  • Number of Estimates 10
  • High Estimate $-0.43
  • Low Estimate $-0.84
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +35.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.00 +2.11%
on 05/08/26
84.75 -20.48%
on 04/28/26
-6.75 (-9.10%)
since 04/08/26
3-Month
62.77 +7.36%
on 03/03/26
84.94 -20.66%
on 02/12/26
-0.66 (-0.97%)
since 02/06/26
52-Week
31.77 +112.12%
on 05/29/25
84.94 -20.66%
on 02/12/26
+32.54 (+93.37%)
since 05/08/25

Most Recent Stories

More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 67.39 (-0.09%)
BridgeBio Pharma Q1 Earnings Call Highlights

BridgeBio Pharma (NASDAQ:BBIO) reported first-quarter 2026 results highlighted by continued growth for ATTRUBY and increased investment to support three anticipated launches, while also announcing a new...

BBIO : 67.39 (-0.09%)
BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Pharma: Q1 Earnings Snapshot

BBIO : 67.39 (-0.09%)
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum...

BBIO : 67.39 (-0.09%)
BridgeBio Pharma: The Commercial Ramp That Analysts Haven't Priced for Friction

Barchart Research What to Expect from BBIO Earnings BBIO Generated May 6, 2026 Current Price $68.09 EPS Estimate $$-0.70 Consensus Rating Strong Buy Average Move 2.86% BridgeBio Pharma: The Commercial...

BBIO : 67.39 (-0.09%)
BridgeBio to Participate in May and June Investor Conferences

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 67.39 (-0.09%)
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date,...

BBIO : 67.39 (-0.09%)
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 67.39 (-0.09%)
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 67.39 (-0.09%)
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 67.39 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 72.11
2nd Resistance Point 70.61
1st Resistance Point 69.00
Last Price 67.39
1st Support Level 65.89
2nd Support Level 64.39
3rd Support Level 62.78

See More

52-Week High 84.94
Last Price 67.39
Fibonacci 61.8% 64.63
Fibonacci 50% 58.36
Fibonacci 38.2% 52.08
52-Week Low 31.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.